Microdosing Ibogaine for Parkinson's: What One Case Study Found - Tobias Erny

Paul F. Austin and Tobias Erny explore low-dose ibogaine for Parkinson's disease: a published case report, GDNF, who responds, and drug safety. Find full show notes and links here: https://thethirdwave.co/podcast/episode-378/?ref=250 In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Tobias Erny, a Swiss iboga practitioner, researcher, and Co-Director of the Global Iboga Therapy Alliance. Tobias shares how ibogaine helped him end his own opiate addiction, and how that recovery grew into two decades of work with iboga, including a published case report on low-dose ibogaine for Parkinson's disease. Paul and Tobias explore why ibogaine may help some people living with Parkinson's, from GDNF, a growth factor that supports dopamine neurons, to its effects on mood and motivation. They also discuss how ibogaine differs from the whole iboga plant, why many patients don't respond, the medication interactions families should understand first, and why starting low and staying honest about uncertainty matters as research moves toward a clinical trial. Episode Links: Tobias Erny on LinkedIn Ibogaine and Parkinson's disease case report, Journal of Psychedelic Studies Talk with before and after video of a Parkinson's patient Episode Sponsors: The Microdosing Practitioner Certification at Psychedelic Coaching Institute. Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin sits down with Eiad Asbahi, founder of Mindscape, a patient care coordination platform that connects people with licensed providers and pharmacies for low-dose ketamine care. Eiad spent 17 years running a hedge fund and reached the kind of success he had always dreamed about. Then his largest investment collapsed and his marriage ended, and he was forced to look inward. This epsiode is sponsored by Eiad Asbahi. Eiad describes the moment he realized he was the common denominator in his own failures. He talks about the core belief underneath it all, that he was "defective," and how Internal Family Systems therapy showed him there are no bad parts. He explains how building inner safety changed the way he parents his daughter, and why he uses ketamine to reconnect rather than to escape. Paul and Eiad also discuss the thinking behind Mindscape's daily low-dose model and the case for repetition over peak experiences. The conversation ends with a candid disagreement about dependence, personal agency, clinical oversight, and what responsible access to ketamine should look like. Eiad Asbahi is a founder and father. He spent 17 years running a hedge fund and reached the highest levels of professional success before a long professional collapse. Around the same time, a divorce sent him inward. He wanted to model a secure relationship for his daughter, so he began Internal Family Systems therapy and spent the next five years rebuilding his relationship with himself. Eiad founded Mindscape to make the kind of guided, medically supervised care that changed his life easier to find and navigate. Mindscape is a patient care coordination platform that connects people with independently licensed providers and pharmacies, and its approach is built on repetition over intensity. Today his work centers on what comes after healing: deliberately rebuilding identity, motivation, and meaning. Highlights: From hedge fund highs to a five-year professional collapse Realizing he was the common denominator in his failures The core belief beneath it all: feeling defective Internal Family Systems and the idea that there are no bad parts How repeated inner work builds inner safety Becoming the protector for his daughter that he never had How Mindscape's stripped-down model differs from other ketamine platforms Daily low-dose ketamine: repetition over intensity, connection over escape Eiad's self-care practices: movement, music, and red light Dependence, agency, and accountability: where Paul and Eiad disagree Episode Links: Mindscape: https://themindscape.com/ Mindscape on Instagram: https://www.instagram.com/themindscape.official Eiad on Instagram: https://www.instagram.com/eiadasbahi 

In this episode of The Psychedelic Podcast, Paul F. Austin sits down with Mira Funk, LCSW, a Harvard-educated psychotherapist and the founder of Unjourneying, a private practice built around 5-MeO-DMT, N,N-DMT, and salvia divinorum. This episode is sponsored by Mira Funk. Mira traces her path from fourteen years of Zen meditation into psychedelic work, and explains how a severe reaction to a common nootropic supplement unexpectedly reoriented her entire practice toward presence rather than dramatic, otherworldly trips. She and Paul go deep on the extended-release routes she has pioneered, including subcutaneous, rectal, and vaginal 5-MeO-DMT, and the titrated e-mesh method she uses for salvia divinorum. Throughout the conversation, Mira is candid about the real risks of self-administration, the role of chronic illness in shaping her gentle approach, and why she believes structure matters most for those newest to this work. Mira Funk, LCSW (she/her), is a Harvard-educated queer, nonbinary psychotherapist and psychedelic guide specialized in 5-MeO-DMT, N,N-DMT (including analog ayahuasca), and salvia divinorum. Based in Oregon, she is the founder of Unjourneying, a private therapy practice blending somatic, nondual, and neuroscience-informed methods to optimize psychedelic healing and insight. Unjourneying draws its name from Neem Karoli Baba's reported non-response to LSD; observing this same effect in herself and long-term clients, Mira embraced the radically vivid here and now as her lodestar, rather than some mystical elsewhere. Having battled neurological Lyme disease for over three decades, Mira brings a gentle, trauma-informed approach to clients with physical and emotional challenges. She is the inventor of The Hourglass, a lung-friendly 5-MeO-DMT vaporization system with zero liquid carriers and two-stage cooling, and offers multiple extended-release routes of 5-MeO-DMT, including subcutaneous, rectal, and vaginal preparations for sexual trauma and pelvic floor dysfunction. She is currently the only psychedelic therapist in the field offering titrated dosing of pure salvinorin-A in an e-mesh format. Highlights: Fourteen years of Zen before mushrooms filled the gap Why structure helps most early in psychedelic work A supplement reaction that reshaped her entire practice 5-MeO-DMT as explosion versus something you can surf Building The Hourglass: her own zero-liquid vaporizer Subcutaneous, rectal & vaginal routes for 5-MeO-DMT A rectal 5-MeO-DMT session and healing pelvic trauma Real risks of DIY dosing and sourcing injectables safely Titrating salvia to a whisper with a custom e-mesh device Episode Links:  Unjourneying (Mira's website): https://www.unjourneying.com/ Mira on Instagram: https://www.instagram.com/unjourneying YouTube: https://www.youtube.com/@unjourneying Patreon: https://www.patreon.com/c/unjourneying/membership This episode is also sponsored by: SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

Paul talks with biohacking pioneer Dave Asprey about medicalization, microdosing, consciousness, and Dave's new BEYOND Wonderland psychedelics conference in Austin. In this bonus episode, Paul welcomes back Dave Asprey, founder of Bulletproof Coffee and creator of the biohacking movement, to talk about BEYOND Wonderland, the psychedelics conference Dave has revamped for October 12-14 in Austin. They also get into medicalization, the CIA's documented role in psychedelic history, what responsible microdosing regulation could look like, and why Dave is as focused on unlocking latent human ability as he is on fixing what's broken. Want to attend BEYOND Wonderland? Get 10% off your ticket with code THIRDWAVE at wonderlandconference.com (Code expires October 10). Episode links: BEYOND Wonderland – Use code THIRDWAVE for 10% off: https://wonderlandconference.com/ Dave Asprey's website: https://daveasprey.com/  Third Wave occasionally partners with or shares information about other people, companies, and/or providers. While we work hard to only share information about ethical and responsible third parties, we can't and don't control the behavior of, products and services offered by, or the statements made by people, companies, or providers other than Third Wave. Accordingly, we encourage you to research for yourself, and consult a medical, legal, or financial professional before making decisions in those areas. Third Wave isn't responsible for the statements, conduct, services, or products of third parties. We receive a commission from sales arising from customers who use our coupon code. No one is required to use the coupon code. Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with computer scientist, climate investor, and Nexus author Ramez Naam about psychedelics, AI, neurotechnology, and cognitive liberty. Find full show notes and links here: https://thethirdwave.co/podcast/episode-374/?ref=278 Ramez shares how psychedelic experiences sparked his interest in neuroscience, inspired his books, and helped redirect his work toward climate and clean energy. He and Paul explore what brain-computer interfaces can do today, the future of psychedelic mental healthcare, and how to protect freedom of thought as AI becomes a more personal tool. Ramez Naam is a computer scientist, mission-focused investor, climate activist, and award-winning author of science fiction and nonfiction. His Nexus trilogy explores the possibilities of mind-to-mind communication technology, while his nonfiction examines human augmentation, neuroscience, climate, and clean energy. He serves as Co-Chair for Energy and Environment at Singularity University and invests through Planetary VC in companies working on clean energy, climate technology, and beneficial uses of AI. Highlights: How psychedelics inspired Ramez's interest in neuroscience and his five books What today's brain-computer interfaces can and cannot do Psilocybin, 5-MeO-DMT, and the future of mental healthcare Medicalization, decriminalization, and psychedelic access The LSD experience that helped shape Ramez's climate work Clean energy progress and the challenges that remain AI privacy, cognitive liberty, and the freedom to think Episode Links: Ramez Naam's website: rameznaam.com Ramez Naam on X: x.com/ramez Ramez Naam on Instagram: instagram.com/rameznaam Episode Sponsors: SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with therapist and InnerEthics® founder Kylea Taylor about why responsible psychedelic therapy requires more than good intentions. Find full show notes and links here: https://thethirdwave.co/podcast/episode-373/?ref=278 Kylea explains why non-ordinary states can amplify intimacy, vulnerability, countertransference, and practitioner blind spots. She presents ethics as an ongoing practice of self-inquiry, restraint, and right relationship rather than a set of rules consulted only after something goes wrong. Paul and Kylea also examine personal experience as preparation for facilitation, the complexities of touch and consent, the meaning of inner healing intelligence, and why compassionate peer consultation is essential for anyone holding space in psychedelic work. Kylea Taylor, M.S., LMFT, is a California licensed therapist and the founder of InnerEthics®, a self-reflective approach to relational ethics taught in breathwork and psychedelic practitioner trainings. A certified Holotropic Breathwork® facilitator, she served as a senior trainer with Dr. Stanislav Grof throughout the 1990s. Kylea is the author of The Ethics of Caring and Peer Consultation Groups & Ethical Awareness Tools for Psychedelic Practitioners. She also co-founded SoulCollage®, helping train more than 6,000 facilitators across 63 countries. Highlights: Why non-ordinary states amplify ethical challenges Self-awareness and the practitioner's blind spots Whether facilitators need personal experience with altered states Touch, consent, and client autonomy in psychedelic therapy Supporting inner healing intelligence without over-intervening Recognizing transference and countertransference Right relationship as a practical ethical compass Peer consultation and compassionate accountability Watch the full conversation on YouTube: https://youtu.be/CmLVfgTpgrc Connect with Kylea: InnerEthics®: https://innerethics.com  KyleaTaylor.com: https://kyleataylor.com  Kylea Taylor's books: https://hanfordmead.com/product-category/authors/kylea-taylor/  InnerEthics® on Instagram: https://www.instagram.com/innerethics/ Kylea Taylor on LinkedIn: https://www.linkedin.com/in/kyleataylor/  Episode Sponsors: SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Paije Alexandra West, founder of ETÉREO, about iboga, ibogaine, and Bwiti initiation. Drawing on Paul's recent retreat experience at ETÉREO in Baja, they examine what can be lost when iboga is reduced to a clinical alkaloid and how traditional ceremony can coexist with rigorous medical screening. Paije explains the differences between iboga root bark and total alkaloid extract, the role of Bwiti music, and why discomfort, community, and long-term integration are central to working responsibly with this demanding medicine. Paije Alexandra West is the founder and lead iboga provider at ETÉREO | Center for Truth, an iboga retreat center outside Todos Santos, Baja California Sur. A twice-initiated Bwiti practitioner, she began on the clinical side, supporting guests through detox and aftercare at ibogaine clinics. Her commitment deepened after losing her brother to a fentanyl overdose. Paije trained in Gabon with the Missoko Bwiti, completed the Nyembe rites in 2022, and was initiated with the Fong in 2025. Her work combines traditional Bwiti ceremony with EKGs, pharmacist reviews, licensed therapists, and IFS-informed integration. She runs ETÉREO with her husband and co-founder, Fletcher Burdick, and co-founded the Stone West Foundation. Highlights: How iboga differs from isolated ibogaine treatment What medicalized approaches can lose when culture and ceremony are removed Combining Bwiti tradition with clinical screening and emergency preparation Why responsible providers must be willing to say no Iboga root bark versus total alkaloid extract How Bwiti music shapes the ceremonial experience Discomfort, community, and the limits of modern convenience Why iboga requires long-term integration rather than a quick-fix mindset Episode Links: ETÉREO Stone West Foundation ETÉREO on Instagram @etereo__baja Paije on Instagram: @paijealexandrawest Find full show notes and links here: https://thethirdwave.co/podcast/episode-372/?ref=278 Episode Sponsors: SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with psychiatrist and TaperClinic founder Dr. Josef Witt-Doerring about antidepressant withdrawal, psychiatric deprescribing, and psychedelic readiness. Find full show notes and links here: https://thethirdwave.co/podcast/episode-371/?ref=278 Josef explains what he learned reviewing drug safety at the FDA, why withdrawal can be mistaken for relapse, and how tapering often becomes more difficult at lower doses. They also explore the lifestyle foundations of mental health, benzodiazepine withdrawal, and why psychedelic clinics may need far more sophisticated support as increasingly medicated patients seek psilocybin, MDMA, LSD, and ketamine. Dr. Josef Witt-Doerring, MD, is a psychiatrist renowned for his expertise in drug tapering and withdrawal management. With years of experience in clinical psychiatry, he has developed a particular interest and specialization in assisting patients with the safe and effective tapering of psychiatric medications. His approach is patient-centered, focusing on individualized plans that prioritize patient well-being and functioning. He is the founder and medical director of TaperClinic. Highlights: What antidepressant research leaves unanswered Why withdrawal can resemble relapse How lower doses change tapering Five foundations before optimization hacks Benzodiazepines in psychiatric deprescribing Psychedelics versus conventional drug models Insurance pressure on psychedelic clinics Preparing for heavily medicated patients TaperClinic: https://taperclinic.com/ TaperClinic Free Guide: https://taperclinic.com/free-guide/ SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin: https://edu.psychedeliccoaching.institute/ssri-deprescribing-and-psychedelic-readiness-certification/?ref=12 Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with investigative journalist Robert Whitaker about the evidence behind psychiatric prescribing, SSRI withdrawal, and what psychedelic medicine can learn from that history. Find full show notes and links here: https://thethirdwave.co/podcast/episode-370/?ref=278 Whitaker revisits the chemical imbalance theory, long-term antidepressant outcomes, and how psychiatric drugs evolved from short-term interventions toward chronic use. He also explores the social and environmental dimensions of mental health before turning to psychedelic medicine and the risks of recreating a drug-centered model of care. Robert Whitaker is the author of five books, three examining the history of psychiatry. His 2010 book, Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness, won the U.S. Investigative Reporters and Editors award for best investigative journalism. He is president of the Mad in America Foundation and founder of MadinAmerica.com, which features research news and perspectives from an international group of writers interested in rethinking psychiatry. Highlights: How the chemical imbalance story took hold What long-term psychiatric outcomes reveal How antidepressants became long-term treatment SSRI withdrawal versus recurring depression When SSRIs help, and at what cost Mental health beyond individual brain chemistry Psychedelic medicalization and personal agency Community, ritual, and psychedelic experience Episode Links: Mad in America Robert Whitaker Books SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Dr. Remi Drozd back to explore ketamine, SSRIs, and the changing landscape of psychedelic mental health care. Find full show notes and links here: https://thethirdwave.co/podcast/episode-369/?ref=278 Since Remi first appeared on the podcast in Episode 182, Lucid Therapeutics has grown from a small ketamine practice into a ten-room interventional mental health clinic offering ketamine treatments, Spravato, TMS, therapy, integration support, and other approaches. Paul and Remi examine one of the less-discussed challenges facing psychedelic medicine: many prospective patients are already taking antidepressants and other psychiatric medications. Remi explains why SSRI tapering needs to be individualized, how ketamine may support some patients through treatment transitions, and what clinicians may need to consider as psilocybin and other psychedelic therapies move closer to mainstream clinical use. Dr. Remi Drozd is a board-certified physician and founder of Lucid Therapeutics in Santa Barbara. After 15 years practicing emergency medicine, he shifted toward more integrative approaches to mental health care. He has trained in ketamine therapy and MDMA-assisted therapy through MAPS. His work focuses on individualized care, expanding access, and preparing for how emerging psychedelic treatments may fit into the existing mental healthcare system. Highlights: The growth of Lucid Therapeutics Expanding access through insurance-based care Navigating ketamine alongside SSRIs Why SSRI tapering must be individualized Withdrawal versus the return of depression Preparing patients for future psilocybin therapy The infrastructure required for psychedelic treatment Bringing longer psychedelic sessions into existing clinics Episode Links: SSRI Deprescribing & Psychedelic Readiness Training: https://edu.psychedeliccoaching.institute/ssri-deprescribing-and-psychedelic-readiness-certification/?ref=8 Lucid Therapeutics: https://www.thelucid.life/ Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.